NRAS and acute myeloid leukemia: However, in a recent manuscript (made available on bioRxiv in April 2023) by Stephen Lane’s group, the authors reported a preference for imetelstat to target NRAS mutated clones in a pre-clinical AML PDX mouse model (50).